机构：[1]Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China[2]Peking Union Med Coll, Beijing, Peoples R China[3]Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, Natl Caner Ctr, Beijing, Peoples R China[4]Harbin Med Univ Canc Hosp, Harbin, Heilongjiang, Peoples R China[5]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China河北医科大学第四医院[6]China Jinagsu Prov Inst Canc Res, Jiangsu, Peoples R China[7]RemeGen Ltd, Yantai, Peoples R China[8]Tonji Univ, Sch Life Sci & Technol, Shanghai, Peoples R China
第一作者机构：[1]Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China[2]Peking Union Med Coll, Beijing, Peoples R China[3]Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, Natl Caner Ctr, Beijing, Peoples R China[4]Harbin Med Univ Canc Hosp, Harbin, Heilongjiang, Peoples R China[5]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China[6]China Jinagsu Prov Inst Canc Res, Jiangsu, Peoples R China[7]RemeGen Ltd, Yantai, Peoples R China[8]Tonji Univ, Sch Life Sci & Technol, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Xu Binghe,Wang Jiayu,Zhang Qingyuan,et al.An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer[J].JOURNAL OF CLINICAL ONCOLOGY.2018,36(15):doi:10.1200/JCO.2018.36.15_suppl.1028.
APA：
Xu, Binghe,Wang, Jiayu,Zhang, Qingyuan,Liu, Yunjiang,Feng, Ji Feng...&Fang, Jianmin.(2018).An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer.JOURNAL OF CLINICAL ONCOLOGY,36,(15)
MLA：
Xu, Binghe,et al."An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer".JOURNAL OF CLINICAL ONCOLOGY 36..15(2018)
医学